No association found between thiazolidinediones and bladder cancer
the ONA take:
According to a new study published in the journal Diabetologia, there is no link between either pioglitazone or rosiglitazone and bladder cancer.
For the study, the researchers collected prescription, cancer, and mortality data from 1.01 million people with type 2 diabetes from six populations in Europe and North America. Of those, 3,248 developed bladder cancer and only 117 of those were in patients who had taken pioglitazone.
Results showed that there was no link between cumulative exposure to the thiazolidinediones and bladder cancer in men or women after adjustment for other factors. In addition, longer exposure to pioglitazone did no increase the risk for developing bladder cancer.
According to the American Cancer Society, there will be an estimated nearly 75,000 new cases of bladder cancer and about 15,600 deaths from the disease. Men are about 3 to 4 times more likely to develop bladder cancer than women, but that risk is about 1 in 26 men.
Previous studies have shown that drugs from this class of antidiabetic drugs increases the risk of bladder cancer, but this study demonstrates otherwise. The authors suggest that studies with a longer duration of follow-up of patients exposed to pioglitazone or rosiglitazone be conducted to end the controversy.
There is no link between either pioglitazone or rosiglitazone and bladder cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|